logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Homepage featured | Collections | MSF Science Portal
Homepage featured

Homepage featured

Collection Content

Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (6)
  • CSV
  • BibTeX
  • EndNote
Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (6)
  • CSV
  • BibTeX
  • EndNote

See more collections

World Hepatitis Day 2023
World Hepatitis Day 2023
Viral hepatitis is a major cause of disease and death globally. To mark World Hepatitis Day (July 28th) we present a selection of recent MSF research exploring how to effectively deploy powerful medical tools that could turn the tide on hepatitis C and E—but now reach only a tiny fraction of people who desperately need them, especially in low-resource and emergency settings. For hepatitis C, where groundbreaking new antiviral drugs can cure nearly all patients, MSF is piloting simplified, community-based models of care that offer rapid screening, diagnosis, and treatment under one roof. Some programs focus on the complex needs of highly vulnerable, hard-to-reach populations, such as people co-infected with HIV or TB or who inject drugs. Turning to prevention, an ongoing vaccination campaign against hepatitis E in an outbreak setting is showing early signs of short-term protection. Final results from this South Sudanese refugee camp, where poor sanitation and water quality regularly lead to outbreaks, should help plug a key evidence gap that—along with other barriers discussed in a commentary article—impedes widespread uptake of the vaccine.
Power & communities (MSF Scientific Days International 2022)
Power & communities (MSF Scientific Days International 2022)
No description available
TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosis
TB-PRACTECAL Trial—Evidence for a shorter, safer, more effect...
Drug-resistant tuberculosis (DR-TB) remains an especially deadly form of the ancient scourge of TB, while current treatments are long, toxic, and ineffective for half of all patients. Aiming to change this unacceptable status quo, in the mid-2010’s MSF and partners launched three clinical trials to test novel regimens containing the first new TB drugs in decades. On 22 December 2022 the New England Journal of Medicine published findings from TB-PRACTECAL, a three-country randomized controlled trial, showing that a shorter regimen is safer and cured 89% of DR-TB patients, compared with 52% on the standard of care. These findings have already been incorporated into the World Health Organization’s new TB treatment guidelines. A separate study shows that the new regimen is also more cost-effective. Alongside these results the content collection linked below highlights other aspects of the trial, from community engagement strategies that helped shape TB-PRACTECAL to setbacks arising from the Covid-19 pandemic. It also examines urgent challenges in scaling up access to these life-saving drugs, including affordability and patent barriers.
View All Collections
Journal Article
|
Research

Risk stratification of childhood infection using host markers of immune and endothelial activation in Asia (Spot Sepsis): a multi-country, prospective, cohort study

Chandna A, Koshiaris C, Mahajan R, Ahmad RA, Van Anh DT,  et al.
2025-09-01 • Lancet Child and Adolescent Health
2025-09-01 • Lancet Child and Adolescent Health

BACKGROUND

Prognostic tools for febrile illnesses are urgently required in resource-constrained community contexts. Circulating immune and endothelial activatio...

Journal Article
|
Letter

War wounds caused by explosive weapons in Gaza: data from a 2024 study by Médecins Sans Frontières

Nicolai M, Safi SSS, Casera M, Dekhili D, Hook C,  et al.
2025-07-01 • Lancet
2025-07-01 • Lancet
Journal Article
|
Pre-Print

Feasibility and acceptability of menstrual underwear in a conflict and population displacement prone setting of Kalehe, Democratic Republic of the Congo

Bisimirwe C, Maombi S, Nabuki S, Mubelelwa L, Llosa AE,  et al.
2025-06-29 • Research Square
2025-06-29 • Research Square

Menstrual hygiene management remains a critical yet often neglected issue in humanitarian setting. Reusable menstrual underwear (MU) offers a potentially sustainable and discrete solu...

Conference Material
|
Abstract

Newly discovered paediatric melioidosis in Mali: the tip of an African iceberg?

Lichtenegger S, Michel J, Mollo B, Sanogo A, Diawara H,  et al.
2025-05-22 • MSF Scientific Days International 2025
2025-05-22 • MSF Scientific Days International 2025
Journal Article
|
Short Report

Providing emergency medical care at the Belarus-Poland border

Zadykowicz R, Kuc J, Ladomirska J, Zamatto F, Lim SY
2025-05-01 • Forced Migration Review
2025-05-01 • Forced Migration Review
Journal Article
|
Research

High caseload of Scabies amongst Rohingya refugees in Cox’s Bazar, Bangladesh: a retrospective analysis of the epidemiological and clinical characteristics of cases, July 2022 to November 2023

Alhaffar BA, Islam S, Hoq MI, Das A, Shibloo SM,  et al.
2025-04-09 • PLOS Global Public Health
2025-04-09 • PLOS Global Public Health

Scabies is a dermatological parasitic infestation prevalent in many regions worldwide. Classified as a neglected disease by World Health Organization (WHO) since 2017, it is often ass...